This discovery dispute ruling has no material financial impact on TEVA. The underlying antitrust case against Corcept continues. Monitor for summary judgment motions or trial dates, which could affect the stock if material exposure emerges.
Price Chart
Executive Summary
A federal magistrate judge partially granted and partially denied Corcept Therapeutics' motion to compel discovery from Teva's CEO Richard Francis. Teva's CEO must sit for a limited two-hour deposition regarding his critique of Teva's generic mifepristone promotion strategies, but Teva is not required to produce his custodial documents. This is a routine procedural discovery ruling in an ongoing antitrust case with no immediate financial impact.
Court Ruling Details
Key Facts
- Teva is the plaintiff in an antitrust case against Corcept regarding generic mifepristone for Cushing's syndrome.
- Corcept sought to depose Teva's CEO Richard Francis and obtain his documents; the court granted a limited 2-hour deposition on one topic and denied document production.
- The deposition is limited to Mr. Francis's critique of Teva's strategy for promoting generic mifepristone and his ideas for solutions.
- Fact discovery in the case closed on May 15, 2026.
Financial Impact
None stated. The ruling involves only discovery scope, no monetary award or injunctive relief.
Risk Factors
- CEO deposition may reveal internal discussions that could weaken Teva's causation argument in the antitrust case.
- Continued litigation costs and management distraction from the underlying antitrust case.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-10e56aaee5-TEVA |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.51 (+8.69%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.51 (+7.48%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.51 (+5.39%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.51 (+8.42%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.51 (+3.70%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.51 (+3.70%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.51 (+9.32%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.51 (+13.50%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.51 (+12.85%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.51 (+13.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access